JP2007534951A - タンパク質ｐｔｘ３測定用の単クローン抗体、ハイブリドーマ、改良方法、及び前記測定用キット - Google Patents
タンパク質ｐｔｘ３測定用の単クローン抗体、ハイブリドーマ、改良方法、及び前記測定用キット Download PDFInfo
- Publication number
- JP2007534951A JP2007534951A JP2007509981A JP2007509981A JP2007534951A JP 2007534951 A JP2007534951 A JP 2007534951A JP 2007509981 A JP2007509981 A JP 2007509981A JP 2007509981 A JP2007509981 A JP 2007509981A JP 2007534951 A JP2007534951 A JP 2007534951A
- Authority
- JP
- Japan
- Prior art keywords
- ptx3
- solution
- plate
- well
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 29
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 23
- 101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 title description 22
- 102100027351 Pentraxin-related protein PTX3 Human genes 0.000 title description 22
- 238000005259 measurement Methods 0.000 title description 5
- 108700025763 PTX3 Proteins 0.000 claims abstract description 24
- 239000013060 biological fluid Substances 0.000 claims abstract description 13
- 239000000243 solution Substances 0.000 claims description 30
- 239000011534 wash buffer Substances 0.000 claims description 25
- 238000005406 washing Methods 0.000 claims description 14
- 239000007853 buffer solution Substances 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 7
- 230000009871 nonspecific binding Effects 0.000 claims description 7
- 239000012089 stop solution Substances 0.000 claims description 7
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 claims description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 6
- 101100352284 Homo sapiens PITX3 gene Proteins 0.000 claims description 6
- 101100031710 Homo sapiens PTX3 gene Proteins 0.000 claims description 6
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 6
- 230000000903 blocking effect Effects 0.000 claims description 6
- 229940098773 bovine serum albumin Drugs 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 6
- 238000002965 ELISA Methods 0.000 claims description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 108010090804 Streptavidin Proteins 0.000 claims description 5
- 239000003593 chromogenic compound Substances 0.000 claims description 5
- 239000008363 phosphate buffer Substances 0.000 claims description 5
- 238000007865 diluting Methods 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- 230000001965 increasing effect Effects 0.000 claims description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 20
- BFHAYPLBUQVNNJ-UHFFFAOYSA-N Pectenotoxin 3 Natural products OC1C(C)CCOC1(O)C1OC2C=CC(C)=CC(C)CC(C)(O3)CCC3C(O3)(O4)CCC3(C=O)CC4C(O3)C(=O)CC3(C)C(O)C(O3)CCC3(O3)CCCC3C(C)C(=O)OC2C1 BFHAYPLBUQVNNJ-UHFFFAOYSA-N 0.000 description 18
- 239000002609 medium Substances 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 108010074051 C-Reactive Protein Proteins 0.000 description 8
- 102100032752 C-reactive protein Human genes 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 201000000050 myeloid neoplasm Diseases 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108090001108 Troponin T Proteins 0.000 description 3
- 102000004987 Troponin T Human genes 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000028399 Critical Illness Diseases 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102400001263 NT-proBNP Human genes 0.000 description 2
- 108010045517 Serum Amyloid P-Component Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 102000041715 pentraxin family Human genes 0.000 description 2
- 108091075331 pentraxin family Proteins 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 101000883910 Arabidopsis thaliana Chlorophyll synthase, chloroplastic Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000944536 Homo sapiens Uncharacterized protein C6orf47 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 102100036202 Serum amyloid P-component Human genes 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100033656 Uncharacterized protein C6orf47 Human genes 0.000 description 1
- 206010047112 Vasculitides Diseases 0.000 description 1
- GVBNSPFBYXGREE-CXWAGAITSA-N Visnadin Chemical compound C1=CC(=O)OC2=C1C=CC1=C2[C@@H](OC(C)=O)[C@@H](OC(=O)[C@H](C)CC)C(C)(C)O1 GVBNSPFBYXGREE-CXWAGAITSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000007973 glycine-HCl buffer Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000858A ITMI20040858A1 (it) | 2004-04-29 | 2004-04-29 | Anticorpi monoclonali ibridomi metodo migliorato per determinare la proteina ptx3 e kit per detta determinazione |
| PCT/EP2005/004637 WO2005106494A2 (en) | 2004-04-29 | 2005-04-27 | Monoclonal antibodies, hybridomas, improved method for determining the protein ptx3 and kit for said determination |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011032661A Division JP2011117973A (ja) | 2004-04-29 | 2011-02-17 | タンパク質ｐｔｘ３測定用の単クローン抗体、ハイブリドーマ、改良方法、及び前記測定用キット |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007534951A true JP2007534951A (ja) | 2007-11-29 |
| JP2007534951A5 JP2007534951A5 (enExample) | 2008-05-01 |
Family
ID=35242298
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007509981A Pending JP2007534951A (ja) | 2004-04-29 | 2005-04-27 | タンパク質ｐｔｘ３測定用の単クローン抗体、ハイブリドーマ、改良方法、及び前記測定用キット |
| JP2011032661A Pending JP2011117973A (ja) | 2004-04-29 | 2011-02-17 | タンパク質ｐｔｘ３測定用の単クローン抗体、ハイブリドーマ、改良方法、及び前記測定用キット |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011032661A Pending JP2011117973A (ja) | 2004-04-29 | 2011-02-17 | タンパク質ｐｔｘ３測定用の単クローン抗体、ハイブリドーマ、改良方法、及び前記測定用キット |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7915004B2 (enExample) |
| EP (1) | EP1740956A2 (enExample) |
| JP (2) | JP2007534951A (enExample) |
| KR (1) | KR101168292B1 (enExample) |
| CN (1) | CN1947018B (enExample) |
| AU (1) | AU2005238637B2 (enExample) |
| CA (1) | CA2562895A1 (enExample) |
| IT (1) | ITMI20040858A1 (enExample) |
| WO (1) | WO2005106494A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010513917A (ja) * | 2006-12-22 | 2010-04-30 | ヒューマニタス・ミラソーレ・エス．ピー．エー． | ロングペントラキシンｐｔｘ３の血漿レベルを測定するための方法 |
| CN112739714A (zh) * | 2018-09-14 | 2021-04-30 | 元健生物医药科技(苏州)有限公司 | 含单株抗体或其抗原结合片段的医药组合物及其用途 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1947460B1 (en) * | 2005-11-11 | 2012-05-30 | The University of Tokyo | Method of measuring ptx3 with high sensitivity |
| JP5199120B2 (ja) * | 2005-12-29 | 2013-05-15 | ヒューマニタス・ミラソーレ・エス．ピー．エー． | 妊娠における炎症性内皮機能障害に対する診断試験 |
| WO2008099608A1 (ja) * | 2007-02-15 | 2008-08-21 | Saitama Medical University | 炎症性腸疾患の診断方法 |
| JP5832479B2 (ja) | 2012-08-09 | 2015-12-16 | 日本特殊陶業株式会社 | ガスセンサ |
| TWI528969B (zh) * | 2013-06-07 | 2016-04-11 | 國立成功大學 | 胺基酸序列用於製備抑制ｐｔｘ３治療鼻咽癌之醫藥組合物之用途 |
| CN106950366B (zh) * | 2017-02-15 | 2019-03-22 | 中国医学科学院北京协和医院 | 一种acpa阴性的ra诊断标志物及其应用 |
| TWI741216B (zh) * | 2017-09-19 | 2021-10-01 | 臻崴生物科技有限公司 | 專一性抑制或減緩ｐｔｘ３與ｐｔｘ３受體結合之單株抗體或其抗原結合片段及其用途 |
| CN111024956A (zh) * | 2019-12-31 | 2020-04-17 | 江苏美克医学技术有限公司 | 一种检测ptx3的时间分辨荧光免疫层析试剂盒 |
| US20230251274A1 (en) * | 2020-06-25 | 2023-08-10 | Humanitas Mirasole S.P.A. | Ptx3 as prognostic marker in covid-19 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05340945A (ja) * | 1992-06-05 | 1993-12-24 | Shiseido Co Ltd | 微量物質測定方法及び測定キット |
| JPH0875737A (ja) * | 1994-09-06 | 1996-03-22 | Fuji Yakuhin Kogyo Kk | ヒト前立腺特異抗原とヒトプロテインｃインヒビターとの複合体の測定方法および同測定用キット |
| JPH09220096A (ja) * | 1996-02-16 | 1997-08-26 | Meiji Milk Prod Co Ltd | コレラトキシン及びその中和活性の新規 高感度測定法及び同キット |
| JP2002014098A (ja) * | 2000-06-28 | 2002-01-18 | Fujirebio Inc | 免疫測定方法及びそのためのキット |
| WO2005080981A1 (ja) * | 2004-02-25 | 2005-09-01 | Perseus Proteomics Inc. | 血管障害の程度の判定方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4427182B2 (ja) * | 1997-09-22 | 2010-03-03 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 抗原を安定化するための緩衝液 |
| ITRM20020109A1 (it) | 2002-02-28 | 2003-08-28 | Sigma Tau Ind Farmaceuti | Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori. |
| US20040137544A1 (en) | 2002-10-31 | 2004-07-15 | Roberto Latini | PTX3 as an early prognostic indicator of cardiovascular and cerebrovascular pathologies |
-
2004
- 2004-04-29 IT IT000858A patent/ITMI20040858A1/it unknown
-
2005
- 2005-04-27 WO PCT/EP2005/004637 patent/WO2005106494A2/en not_active Ceased
- 2005-04-27 CA CA002562895A patent/CA2562895A1/en not_active Abandoned
- 2005-04-27 US US11/587,528 patent/US7915004B2/en not_active Expired - Fee Related
- 2005-04-27 KR KR1020067024272A patent/KR101168292B1/ko not_active Expired - Fee Related
- 2005-04-27 CN CN2005800134880A patent/CN1947018B/zh not_active Expired - Fee Related
- 2005-04-27 AU AU2005238637A patent/AU2005238637B2/en not_active Ceased
- 2005-04-27 JP JP2007509981A patent/JP2007534951A/ja active Pending
- 2005-04-27 EP EP05742234A patent/EP1740956A2/en not_active Withdrawn
-
2011
- 2011-02-17 JP JP2011032661A patent/JP2011117973A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05340945A (ja) * | 1992-06-05 | 1993-12-24 | Shiseido Co Ltd | 微量物質測定方法及び測定キット |
| JPH0875737A (ja) * | 1994-09-06 | 1996-03-22 | Fuji Yakuhin Kogyo Kk | ヒト前立腺特異抗原とヒトプロテインｃインヒビターとの複合体の測定方法および同測定用キット |
| JPH09220096A (ja) * | 1996-02-16 | 1997-08-26 | Meiji Milk Prod Co Ltd | コレラトキシン及びその中和活性の新規 高感度測定法及び同キット |
| JP2002014098A (ja) * | 2000-06-28 | 2002-01-18 | Fujirebio Inc | 免疫測定方法及びそのためのキット |
| WO2005080981A1 (ja) * | 2004-02-25 | 2005-09-01 | Perseus Proteomics Inc. | 血管障害の程度の判定方法 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010513917A (ja) * | 2006-12-22 | 2010-04-30 | ヒューマニタス・ミラソーレ・エス．ピー．エー． | ロングペントラキシンｐｔｘ３の血漿レベルを測定するための方法 |
| CN112739714A (zh) * | 2018-09-14 | 2021-04-30 | 元健生物医药科技(苏州)有限公司 | 含单株抗体或其抗原结合片段的医药组合物及其用途 |
| CN112739714B (zh) * | 2018-09-14 | 2023-11-14 | 元健生物医药科技(苏州)有限公司 | 含单株抗体或其抗原结合片段的医药组合物及其用途 |
| US12152070B2 (en) | 2018-09-14 | 2024-11-26 | Ohealth Biopharmaceutical (Suzhou) Co., Ltd. | Medicinal composition containing monoclonal antibody or antibody fab fragment thereof, and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| US20080261251A1 (en) | 2008-10-23 |
| WO2005106494A3 (en) | 2006-06-01 |
| CN1947018A (zh) | 2007-04-11 |
| ITMI20040858A1 (it) | 2004-07-29 |
| JP2011117973A (ja) | 2011-06-16 |
| WO2005106494A2 (en) | 2005-11-10 |
| EP1740956A2 (en) | 2007-01-10 |
| AU2005238637A1 (en) | 2005-11-10 |
| KR20070006914A (ko) | 2007-01-11 |
| US7915004B2 (en) | 2011-03-29 |
| KR101168292B1 (ko) | 2012-07-25 |
| CN1947018B (zh) | 2012-12-19 |
| CA2562895A1 (en) | 2005-11-10 |
| AU2005238637B2 (en) | 2010-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011117973A (ja) | タンパク質ｐｔｘ３測定用の単クローン抗体、ハイブリドーマ、改良方法、及び前記測定用キット | |
| US20240103018A1 (en) | Galectin-3 immunoassay | |
| ES2542343T3 (es) | Diagnóstico diferencial entre enfermedad pulmonar y cardiovascular | |
| US8029982B2 (en) | Biomarkers for sepsis | |
| JP4338972B2 (ja) | 炎症症状のマーカー | |
| CN102422157B (zh) | 内皮抑制素作为心力衰竭标记的应用 | |
| Shokuhi et al. | Levels of the chemokines growth‐related oncogene α and epithelial neutrophil‐activating protein 78 are raised in patients with severe acute pancreatitis | |
| EP1685409A1 (en) | Proximal markers of arterial thrombosis and inflammation for risk stratification of coronary heart disease | |
| ES2629850T3 (es) | Biomarcadores de señal | |
| Gombos et al. | Adrenomedullin and endothelin-1 are related to inflammation in chronic heart failure | |
| US20050014198A1 (en) | Assays and kits for detecting and monitoring heart disease | |
| US7550269B2 (en) | PTX3 as an early prognostic indicator of cardiovascular and cerebrovascular pathologies | |
| Liu et al. | Association of Soluble IL-1 Receptor Type 2 with Recovery of Left Ventricular Function and Clinical Outcomes in Acute Myocardial Infarction | |
| EP4356139A1 (en) | A method for predicting sepsis and septic shock | |
| HK40072995A (en) | Galectin-3 immunoassay |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080313 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080313 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100730 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100817 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101116 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101124 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110117 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110124 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110726 |